EU approves Acadia’s DAYBU for Rett syndrome symptoms in patients 5 and older

• European Commission granted marketing authorization for Acadia’s DAYBU (trofinetide) in the EU for Rett syndrome neurobehavioral symptoms.
• Label covers adults and children aged 5 and older, positioning DAYBU as the first EU-approved treatment for Rett syndrome.
• Authorization backed mainly by Phase 3 LAVENDER results, citing significant gains on RSBQ and CGI-I endpoints.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608240301BIZWIRE_USPR_____20260824_BW899136) on August 24, 2026, and is solely responsible for the information contained therein.